Endocrine Abstracts

The aim of the present study was to evaluate cardiac valve insufficiency prevalence after 12-month combined treatment with somatostatin analogues (SA) and CAB in acromegalic patients partially responsive to high-dose and long-term SA monotherapy. Twenty-four patients entered the study. A standard echocardiography was performed in all patients at diagnosis, after high-dose and long-term SA therapy and 12 months after CAB addition to SA to evaluate ejection fraction (EF) and mit...

Chronic exposure to hypercortisolism significantly impacts on patient’s health and health-related quality of life (HRQoL). We developed a disease-generated questio-nnaire to evaluate HRQoL in Cushing’s syndrome (CS) (CushingQoL); in 125 (104 females) patients recruited in Spain, France, Germany, The Netherlands and Italy, clinical and hormonal data were collected and correlated with results of the generic SF-36 questionnaire, a question on self-perceived general heal...

Background: Cabergoline, a dopamine receptor-2 agonist, used to treat prolactinomas was associated with increased risk of cardiac valve disease.Objective: To evaluate prevalence of cardiac valve regurgitation in patients with prolactinomas treated with cabergoline.Design: Open, case–control, prospective.Patients: Fifty patients (44 women, 6 men) and 50 sex- and age-matched control subjects.<p class="...

GH and IGF-I excess causes a specific cardiomyopathy, often complicated by diastolic and systolic dysfunction until heart failure. The aim of this study is to evaluate the effects of long-term treatment with pegvisomant on cardiac performance in acromegalic patients. Twelve patients (4 men and 8 women, age 29–58 years) entered the study. A radionuclide angiography at rest and during exercise was performed at baseline and after 18 months of treatment with pegvisomant with ...

The pseudo-Cushing states (PCS) include several clinical conditions such as obesity, polycystic ovary syndrome, depression and alcoholism, characterized by physical features and abnormalities of hypothalamus–pituitary–adrenal axis similar to Cushing’s syndrome (CS). The differential diagnosis between CS and PCS is often complicated and requires several hormonal tests. The aim of this study is to evaluate the diagnostic accuracy of the cortisol response to the or...

Dopamine receptors (DR) are expressed in the majority of corticotroph pituitary tumors and the dopamine agonist cabergoline is effective in controlling cortisol hypersecretion in around 50% of patients with Cushing’s disease (CD). In order to characterize the tumors expressing D2 receptors and the profile of patients which might respond to the treatment with D2 agonists, the current study has the aim to correlate D2 receptor expression and...

Dopamine receptors was suggested to be expressed in medullary thyroid cancer (MTC). The aim of the current study was to evaluate the expression of D2 dopamine receptor in MTC and the effectiveness of the dopamine agonist cabergoline in patients with MTC. Five paraffin-embedded cases of MTC obtained after thyroidectomy were used to evaluate D2 receptor expression by immunohistochemistry. Fifteen patients (7 males, 8 females, 36–78 years) with post-sur...

Cabergoline has been recently demonstrated to normalize cortisol secretion in more than one third of patients with Cushing’s disease (CD). The aim of this study was to evaluate short-term (3-months) and long-term (12-24 months) effects of cabergoline treatment on the main systemic complications of CD, including hypertension, glucose intolerance and dyslipidemia. Twenty patients with CD unsuccessfully treated by neurosurgery entered the study. Cabergoline was admistered at...

High risk of impaired glucose tolerance and diabetes mellitus is frequently observed in acromegalic patients. Some studies have reported a direct correlation between circulating GH levels and the degree of glucose intolerance. Microalbuminuria clusters with the metabolic syndrome and both conditions predict cardiovascular disease mortality. The reported relationships of microalbuminuria with the individual components of the metabolic syndrome are variable. Aim of this prelimin...

Introduction: LNSC has shown high sensitivity and specificity for the initial diagnosis of CD and detection of disease recurrence; however, the use of LNSC to monitor medical treatment of CD is not well established. The results of an exploratory analysis evaluating changes in LNSC in CD patients receiving long-acting pasireotide during a Phase III study (CSOM230G2304; Lacroix et al. Lancet Diabetes Endocrinol 2018) are reported here.Methods: Pat...